Research directory

Clinical trials

Find trials by company, ticker, title or NCT ID.

Filters
Reset
1,647 trials match your filters.
TrialSponsorPhaseStatusPrimary completion
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)NCT07172516XENEPhase 3Recruiting2028-06Estimated
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeNCT07179055Vanda PharmaceuticalsPhase 2Recruiting2026-09Estimated
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997AVBPPhase 3Recruiting2029-02Estimated
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesNCT07187531SABSPhase 2Recruiting2027-11Estimated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyNCT07188558LYELPhase 3Recruiting2029-12Estimated
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFNCT07194382AVLNPhase 2Recruiting2026-12Estimated
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) TrialNCT07197034AARDPhase 3Terminated2026-04-15Actual
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)NCT07200908MIRMPhase 3Recruiting2027-06-30Estimated
Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyNCT07209332Wave Life Sciences USA, Inc.Phase 2Enrolling by invitation2029-03Estimated
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)NCT07209462MIRMPhase 2Recruiting2027-10Estimated
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated CardiomyopathyNCT07210723KARDPhase 2, Phase 3Recruiting2027-09Estimated
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633TGTXPhase 3Active not recruiting2026-10-31Estimated
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseaseNCT07211776Zai Lab (Shanghai) Co., Ltd.Phase 3Active not recruiting2027-03-14Estimated
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationNCT07211958Syndax PharmaceuticalsPhase 3Recruiting2029-06Estimated
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisNCT07217015KYMRPhase 2Active not recruiting2027-06Estimated
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)NCT07217860XENEPhase 3Enrolling by invitation2029-06Estimated
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146Zai Lab (Shanghai) Co., Ltd.Phase 3Recruiting2028-06-30Estimated
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)NCT07218783SGPPhase 3Recruiting2029-03-31Estimated
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)NCT07218796SGPPhase 3Recruiting2029-05-31Estimated
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresNCT07219407RAPPPhase 2Recruiting2028-02-03Estimated
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisNCT07220252TGTXPhase 2, Phase 3Recruiting2030-01-01Estimated
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)NCT07220603PEPGPhase 2Recruiting2029-01Estimated
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500NRIXPhase 2Recruiting2028-01Estimated
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderNCT07221578Vanda PharmaceuticalsPhase 3Active not recruiting2026-12Estimated
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisNCT07223138MoonLake Immunotherapeutics AGPhase 3Enrolling by invitation2028-02-04Estimated
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321Mannkind CorporationPhase 2Recruiting2027-03Estimated
Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderNCT07226661SUPNPhase 2Recruiting2026-12-31Estimated
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerNCT07228832Summit TherapeuticsPhase 3Recruiting2028-05-31Estimated
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyNCT07235085OCULPhase 3Recruiting2027-03Estimated
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)NCT07236606RGNXPhase 3Active not recruiting2028-04-30Estimated

Primary completion marks the end of data collection for the main study measures, not a results publication date.